Live Attenuated Vaccines Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Live attenuated vaccines (LAVs) represent one of the oldest and most widely used vaccine platforms, employing weakened versions of viruses or bacteria such as measles, rubella, yellow fever, rotavirus, BCG, and oral polio. The market is currently worth around $25.73 billion in 2025 and is forecast to grow at a compound annual rate of about 9.75% over the coming decade. Estimates from commercial research firms diverge on the absolute figure, ranging from roughly $8 billion to $32 billion for 2025, reflecting differences in scope, methodology, and whether combination and combination-equivalent products are included.

• •2025 market valuation: approximately $25.73 billion, with double-digit annual growth through 2030.
• •Core products include MMR, varicella, yellow fever, rotavirus, oral polio, BCG, and certain travel vaccines.
• •No government statistical agency publishes a dedicated live attenuated vaccine segment figure; sizes are derived from broader vaccine trade data.

Expansion of routine immunization programmes in low- and middle-income countries is the principal demand-side driver, supported by Gavi, UNICEF, and WHO-led procurement. On the supply side, technological improvements in cold-chain logistics and stabilized formulations have widened the geographic reach of temperature-sensitive LAVs. Heightened outbreak preparedness following recent measles, mumps, and yellow fever resurgences is also accelerating procurement and stockpile investment.

• •Rising paediatric immunization coverage and birth-cohort volume in Asia-Pacific and Africa.
• •Increased public-sector funding for outbreak preparedness and stockpiling of vaccines such as yellow fever and oral polio.
• •Advances in lyophilization and cold-chain infrastructure that improve access in remote settings.

By indication, paediatric vaccines (MMR, varicella, rotavirus, oral polio) dominate revenue, while adult and travel indications such as yellow fever and typhoid contribute a smaller but faster-growing share. Regionally, North America leads in absolute revenue due to high prices and established combination-product uptake, while Asia-Pacific is the fastest-growing region on the back of large birth cohorts, expanding public programmes, and rising domestic manufacturing capacity in India and China.

• •Paediatric indications account for the majority of global revenue; travel and endemic-disease vaccines are the fastest-growing sub-segment.
• •North America holds the largest revenue share; Asia-Pacific is the highest-growth regional market.
• •Europe remains a mature market with steady demand driven by national immunization schedules.

What are the recent trends and outlook?

Near-term, the market is being shaped by the development of next-generation attenuated vaccines targeting dengue, chikungunya, and respiratory syncytial virus, alongside efforts to reduce dependence on ultra-cold-chain logistics. Combination paediatric products that bundle multiple attenuated antigens are gaining traction as a way to improve coverage and reduce administration costs. Over the forecast horizon, sustained 9-12% annual growth is expected, with emerging-market expansion and outbreak-response stockpiling providing the strongest tailwinds.

• •Pipeline expansion into dengue, chikungunya, and RSV using attenuated platforms is a key growth vector.
• •Combination paediatric vaccines are increasingly preferred by public procurers to simplify schedules.
• •Long-term outlook points to continued double-digit growth, driven by emerging-market immunization scale-up.